Navigation Links
Neurelis Announces Completion of Dosing in Study of Intranasal Diazepam
Date:4/20/2011

SAN DIEGO, April 20, 2011 /PRNewswire/ -- Neurelis, Inc. today announced the completion of subject dosing in a randomized crossover study assessing diazepam pharmacokinetics and bioavailability after administration of two proprietary formulations of intranasal diazepam and intravenous injection. Through the collaboration with the University of Minnesota and James Cloyd, PharmD; Neurelis has partnered with the leading experts in clinical research of the nasal delivery of benzodiazepines.  Results from this important study are expected in June.

"We are pleased to work with Dr. Cloyd and the University of Minnesota to complete dosing in the first human trial of our unique nasally administered formulations of diazepam," stated David Hale, Chairman.  "Neurelis has incorporated proprietary technologies to develop intranasal diazepam formulations that can be delivered with a standard sprayer to patients experiencing acute breakthrough seizures.  These intranasal product formulations seek to address the need for a convenient and effective therapy that could help reduce acute breakthrough seizures and avoid the need for costly emergency room visits."

Intranasal diazepam is being developed for the management of patients who require intermittent use of diazepam to control bouts of acute breakthrough seizure activity. There are over 2.7 million people with epilepsy in the United States.  It is estimated that between 30% to 40% of these patients are uncontrolled on oral therapy and are at-risk for acute breakthrough seizures.  Studies have shown that prolonged or repetitive seizures can cause neurological damage and dramatically increase the risk of changes in neuropsychological function or even death.

Presently, there is only one product approved for the treatment of acute repetitive seizures outside of the acute care setting, which is a rectally administered formulation of diazepam called Diastat®.  Because of its rect
'/>"/>

SOURCE Neurelis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 25, 2014  AMETEK, Inc. (NYSE: AME ... Goos as Vice President and General Manager, Engineered ... (EMIP) Division. "I am pleased that Kurt ... business development experience, especially in the medical device industry, ... the continued growth and success of our medical components ...
(Date:7/25/2014)... NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR ... JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF ... ABBV ) today announced financial results for the ... was another very strong quarter for AbbVie, as we delivered ... announced plans to merge with Shire, a strategic action that ...
(Date:7/24/2014)... , July 24, 2014   AcelRx Pharmaceuticals, Inc. ... focused on the development and commercialization of innovative therapies ... confirmed the PDUFA date for Zalviso remains July 27, ... rumor circulated online stating the Food and Drug Administration ... there has been no notification to the company from ...
Breaking Medicine Technology:AMETEK Names Kurtis L. Goos, Vice President & General Manager, Engineered Medical Components 2AbbVie Reports Second-Quarter 2014 Financial Results 2AbbVie Reports Second-Quarter 2014 Financial Results 3AbbVie Reports Second-Quarter 2014 Financial Results 4AbbVie Reports Second-Quarter 2014 Financial Results 5AbbVie Reports Second-Quarter 2014 Financial Results 6AbbVie Reports Second-Quarter 2014 Financial Results 7AbbVie Reports Second-Quarter 2014 Financial Results 8AbbVie Reports Second-Quarter 2014 Financial Results 9AbbVie Reports Second-Quarter 2014 Financial Results 10AbbVie Reports Second-Quarter 2014 Financial Results 11AbbVie Reports Second-Quarter 2014 Financial Results 12AbbVie Reports Second-Quarter 2014 Financial Results 13AbbVie Reports Second-Quarter 2014 Financial Results 14AbbVie Reports Second-Quarter 2014 Financial Results 15AbbVie Reports Second-Quarter 2014 Financial Results 16AbbVie Reports Second-Quarter 2014 Financial Results 17AbbVie Reports Second-Quarter 2014 Financial Results 18AbbVie Reports Second-Quarter 2014 Financial Results 19AbbVie Reports Second-Quarter 2014 Financial Results 20AbbVie Reports Second-Quarter 2014 Financial Results 21AbbVie Reports Second-Quarter 2014 Financial Results 22AbbVie Reports Second-Quarter 2014 Financial Results 23AbbVie Reports Second-Quarter 2014 Financial Results 24AbbVie Reports Second-Quarter 2014 Financial Results 25AbbVie Reports Second-Quarter 2014 Financial Results 26AbbVie Reports Second-Quarter 2014 Financial Results 27AbbVie Reports Second-Quarter 2014 Financial Results 28AbbVie Reports Second-Quarter 2014 Financial Results 29AbbVie Reports Second-Quarter 2014 Financial Results 30AbbVie Reports Second-Quarter 2014 Financial Results 31AbbVie Reports Second-Quarter 2014 Financial Results 32AbbVie Reports Second-Quarter 2014 Financial Results 33AbbVie Reports Second-Quarter 2014 Financial Results 34AbbVie Reports Second-Quarter 2014 Financial Results 35
(Date:7/25/2014)... 25, 2014 The Little Gym of ... on Sunday, July 27 at Discovery Green in downtown ... Copperfield, Katy, Pearland, Friendswood, Spring, The Woodlands, Sugarland-Missouri City, ... , “We’re thrilled to be attending and performing ... Belcher who owns the Sugarland-Missouri City location. “We believe ...
(Date:7/25/2014)... San Diego, CA (PRWEB) July 25, 2014 ... regarding all the latest information from the FDA on ... on July 21, that one lot of Ibuprofen and one ... recalled due to mislabeled packaging. Oxcarbazepine is used ... with epilepsy. , The reason for the recall ...
(Date:7/25/2014)... July 25, 2014 Ticket Down ... Inter Milan tickets in Berkeley at California Memorial Stadium. ... new fans of football, the organizers of the 2014 Guinness ... club teams to North America. With teams representing La Liga, ... will bring some of the best football players from around ...
(Date:7/25/2014)... Tucson, AZ (PRWEB) July 25, 2014 ... Solutions , a Nuanced Media client and the ... medical and dental employee handbooks, announced their partnership ... , TransAct is a registered ISO/MSP of Chase ... in the transaction processing industry. Companies that are ...
(Date:7/25/2014)... 25, 2014 Hastings and Hastings, ... attorney’s fees with regard to personal injury claims, announces ... wide range of legal services for those that have ... another individual or corporation. Free initial consultation services gives ... of a potential personal injury claim . It ...
Breaking Medicine News(10 mins):Health News:The Little Gym of Houston to Attend Houston Family Magazine’s Family Fun Fest 2014 2Health News:Ibuprofen and Oxcarbazepine Tablets Recalled: AttorneyOne Monitors and Keep Consumers Informed 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 3Health News:Nuanced Media Client, CEDR HR Solutions, Partners with TransAct to Serve Medical, Dental, and Eye Care Professionals 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 3
... selected items: ... EURO 1.43, up 1.4% ... $2.14, up 15.7%(1), PARIS, April 30 In order to give ... also report adjusted net income,and adjusted EPS (excluding selected items) in U.S. dollars(1) in ...
... FORT LEE, N.J., April 30 Webster Veterinary, ... Sterling Massachusetts,and one of the largest veterinary distributors ... with Summit VetPharm to distribute their,portfolio of ectoparasiticide ... that we will be working with one of ...
... Stem Cells Developed from Patients, ... ... have succeeded in,inducing stem cells grown from mouse skin cells to ... tomorrow in the journal "Stem Cells.", (Logo: http://www.newscom.com/cgi-bin/prnh/20080422/CLTU133LOGO-a ...
... will celebrate the,achievements of its first year ... cocktail,reception tomorrow Tuesday, April 29. , Astute ... access the,expertise and resources of scientists at ... (ARC CFN). , Located within the Australian ...
... Press Release, NEW YORK, April 30 ... (OTC,Bulletin Board: SPNG) On Tuesday, April 29, SpongeTech ... SpongeTech(R) has received a,signed purchase order, along with ... amount of product purchased by the buyer exceeds ...
... Oversight of Imports, and Gaps in,State Regulations Leave ... Trust for America,s,Health (TFAH) released a new report ... safety system, including obsolete laws, misallocation of,resources, and ... goal should be reducing the number of Americans ...
Cached Medicine News:Health News:Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin 2Health News:Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin 3Health News:Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin 4Health News:Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin 5Health News:Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin 6Health News:Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin 7Health News:Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin 8Health News:Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin 9Health News:Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin 10Health News:Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin 11Health News:Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin 12Health News:Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin 13Health News:Summit VetPharm Announces New Distributor Partnership with Webster Veterinary 2Health News:Mouse Adult Stem Cells Developed into Heart and Blood Cells 2Health News:Mouse Adult Stem Cells Developed into Heart and Blood Cells 3Health News:Astute Nanotechnology celebrates first year of success 2Health News:Astute Nanotechnology celebrates first year of success 3Health News:SpongeTech(R) Delivery Systems, Inc. Clarification of Yesterday's $7,500,000 Order of Uncle Norman's(TM) Pet Sponge 2Health News:Report Finds Food Safety System in Crisis 2Health News:Report Finds Food Safety System in Crisis 3Health News:Report Finds Food Safety System in Crisis 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: